BridgeBio Pharma is a clinical-stage biopharmaceutical company that develops and commercializes drugs for genetic diseases. The company’s pipeline includes a range of therapeutics for various genetic diseases, including oncology, cardiology, neurology, dermatology, and endocrinology. BridgeBio partners with academic institutions, biotechnology companies, and patient advocacy groups to identify and develop promising drug candidates for genetic diseases. The company’s mission is to develop treatments for patients with unmet medical needs, and it is committed to ensuring that its therapies are accessible and affordable. Founded in 2015, BridgeBio is headquartered in Palo Alto, California, and has additional offices in New York, Boston, and North Carolina.